Request Demo

Last update 08 May 2025

LYPLA2 x LYPLA1

Last update 08 May 2025

Basic Info

Related Targets

LYPLA2LYPLA1

Drugs associated with LYPLA2 x LYPLA1

US20250092067

Patent Mining

Target

LYPLA1 x LYPLA2

Mechanism

LYPLA1 inhibitors [+1]

Active Org.

Cornell University

Originator Org.

Cornell University

Active Indication

Eczema [+3]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

ML378

Target

LYPLA1 x LYPLA2

Mechanism

LYPLA1 inhibitors [+1]

Active Org.-

Originator Org.

The Scripps Research Institute

Active Indication-

Inactive Indication-

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with LYPLA2 x LYPLA1

100 Translational Medicine associated with LYPLA2 x LYPLA1

0 Patents (Medical) associated with LYPLA2 x LYPLA1

Literatures (Medical) associated with LYPLA2 x LYPLA1

01 Jun 2025·Food Chemistry

A fluorescent aptasensor for kanamycin detection in milk, seafood and water samples using DNA-AgNCs and exonuclease I-assisted recycling amplification strategy

Article

Author: Chen, Jinri ; Wang, Weixia ; Shan, Lei ; Huang, Qiang ; Wang, Shujun ; Wang, Jing ; Xu, Dong ; Wu, Shaojie ; Guo, Bei ; Li, Fuhou

High kanamycin (KAN) residue in the human body can seriously threaten human health. Therefore, there is an urgent need to develop an accurate, sensitive and simple biosensor to monitor KAN in food. Herein, an aptasensor for KAN has been developed by employing the split aptamer, DNA-templated silver nanoclusters (DNA-AgNCs), and Exonuclease I (Exo I). The aptasensor is composed of a signal recognition and transduction system consisting of split aptamers Apt1, Apt2 and the complementary sequence cDNA of Apt1, and an Exo I-assisted target recovery signal amplification system. The fluorescence signal of the aptasensor can be amplified by 48.98 % by Exo I. And the aptasensor can achieve an ultra-low detection limit of 1.07 nM with a good linear range of 5 nM to 50 nM and 75 nM to 1 μM. Meanwhile, the aptasensor has the characteristics of simple preparation, and convenient use, which has obvious advantages to detect KAN.

20 Mar 2025·Nucleic Acids Research

An enzymatic-independent function of palmitoyl hydrolase in cohesin loading onto chromosome

Article

Author: Hsiao, Wan-Yi ; Huang, Bo-Ru ; Yeh, Shu-Dan ; Wang, Shao-Win ; Wang, Yi-Ting ; Hsu, En-Chi ; Pham, Thanh-Vy

AbstractSister chromatid cohesion is mediated by a conserved multiprotein complex called cohesin. The loading of cohesin onto chromosomes involves the RSC (remodels the structure of chromatin) chromatin remodeling complex. Here, we demonstrate that the fission yeast Phi1, a palmitoyl hydrolase inactive protein 1, serves to bridge the interaction between cohesin and the RSC complex. Phi1 interacts with Rad21 in cohesin and Snf21, the RSC complex ATPase, to promote chromosome loading of cohesin. The identified characteristic features of Phi1 are conserved in the human homologues Apt1 and Apt2, which interact with Rad21 and Brg1, the human homologue of Snf21, in an enzymatic-independent manner. Intriguingly, the cohesin–Apt1–Brg1 complex is upregulated in C4-2B prostate cancer cells, and co-depletion of Apt1 and Apt2 by small interfering RNA triggers mitotic catastrophe in these cells. In addition, Apt1 nuclear localization is associated with poor clinical outcomes in prostate cancer. These results suggest a pro-survival function against mitotic stress for the complex.

01 Dec 2024·Molecular Therapy - Nucleic Acids

Targeting ocular tissues with intravenously administered aptamers selected by in vivo SELEX

Article

Author: Dupont, Daniel Miotto ; Kjems, Jørgen ; Stenberg, Katja ; Seemab, Umair ; Korhonen, Sonja ; Bartos, Piia ; Mäkiniemi, Katariina ; Subrizi, Astrid

Ocular diseases create a significant economic burden and decrease in quality of life worldwide. Drugs and carrier molecules that penetrate ocular tissues after intravenous administration are needed for more efficient and patient-friendly treatment of ocular diseases. Here, ocular barrier-penetrating aptamers were selected through the utilization of in vivo SELEX and intravenous injection in rats. Three aptamers-Apt1, Apt2, and Apt5-were chosen based on their specific accumulation in vascularized ocular tissues and further characterized for their in vivo biodistribution using quantitative reverse-transcription PCR (RT-qPCR). A statistically significant difference between ΔCt values of ocular and control tissues with Apt2 (p < 0.0001) and Apt5 (p < 0.0001) was observed. Interestingly, Apt1 was the most abundant aptamer in the sequencing pool, but it did not show a statistically significant difference in in vivo biodistribution between ocular and control tissues. Overall, this study established a functional in vivo SELEX method for discovering ocular tissue targeting aptamers.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis